De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications
International Journal of Molecular Sciences · 29.05.2026 · 27 (11) · 4924
DOI: 10.3390/ijms27114924 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.05.2026. Verfasst von Kha Cong Le Bui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology B, Hue Central Hospital, Hue 49135, Vietnam. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Lipogenesis, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Clear cell renal cell carcinoma (ccRCC) is increasingly recognized as a lipid-addicted malignancy in which de novo lipogenesis (DNL) supports tumor growth, survival, and treatment resistance. ccRCC-specific genetic alterations, particularly loss of VHL and activation of hypoxia-inducible factor (HIF) signaling, promote SREBP-mediated upregulation of key lipogenic enzymes, including ATP-citrate lyase (ACLY), acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), and stearoyl-CoA desaturase 1 (SCD1). These pathways support membrane biogenesis and redox balance while also promoting metabolic flexibility, enabling adaptation to therapeutic and microenvironmental stresses. Emerging preclinical studies suggest that pharmacological inhibition of lipogenic enzymes, either alone or in combination with tyrosine kinase inhibitors, mTOR inhibitors, HIF-2α antagonists, or immune checkpoint blockade, may suppress ccRCC progression. However, most therapeutic data remain limited to preclinical models, and clinical validation is still lacking. This review synthesizes recent advances in molecular regulation and therapeutic targeting of DNL in ccRCC and discusses the challenges and future opportunities to improve mechanistic understanding and explore potential therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology B, Hue Central Hospital, Hue 49135, Vietnam.
- Division of Haematology and Oncology, Department of Internal Medicine, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea.
- Department of Biochemistry, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea.
ORCID-Profile: Kha Cong Le Bui, Yen Thi Do, Jin Young Kim, Ji Hae Seo
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Bui, K. C. L., Do, Y. T., Kim, J. Y., & Seo, J. H. (2026). De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications. International Journal of Molecular Sciences, 27(11), 4924. https://doi.org/10.3390/ijms27114924
Vancouver
Bui KCL, Do YT, Kim JY, Seo JH. De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications. International Journal of Molecular Sciences. 2026;27(11):4924. doi:10.3390/ijms27114924
BibTeX
@article{Bui2026,
author = {Bui, Kha Cong Le and Do, Yen Thi and Kim, Jin Young and Seo, Ji Hae},
title = {De Novo Lipogenesis in Clear Cell Renal Cell Carcinoma: Mechanistic Insights and Therapeutic Implications},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {11},
pages = {4924},
doi = {10.3390/ijms27114924}
}
EUVIMED